{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:06:27Z","timestamp":1770530787732,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients\u2019 population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed during treatment with daratumumab and were treated with pomalidomide-based combinations in the subsequent lines of therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical stabilization with pomalidomide, including one patient with a long-lasting complete response. Median progression-free survival and overall survival were 6 and 12\u00a0months, respectively. Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These data show that pomalidomide-based combinations can be an effective and safe salvage regimen for daratumumab-refractory patients, including those with EMM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-04637-x","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T19:04:35Z","timestamp":1676315075000},"page":"6569-6574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pomalidomide combinations are a safe and effective option after daratumumab failure"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-7592","authenticated-orcid":false,"given":"Annamaria","family":"Brioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gengenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-0129","authenticated-orcid":false,"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-3004","authenticated-orcid":false,"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2038-9730","authenticated-orcid":false,"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"4637_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398:314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"4637_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"N Engl J Med"},{"key":"4637_CR3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387:2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"4637_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"key":"4637_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"key":"4637_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos M-V et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396:186\u2013197. https:\/\/doi.org\/10.1016\/S0140-6736(20)30734-0","journal-title":"Lancet"},{"key":"4637_CR7","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249","journal-title":"N Engl J Med"},{"key":"4637_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A et al (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33:2266\u20132275. https:\/\/doi.org\/10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"key":"4637_CR9","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","volume":"132","author":"L Garderet","year":"2018","unstructured":"Garderet L, Kuhnowski F, Berge B et al (2018) Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood 132:2555\u20132563. https:\/\/doi.org\/10.1182\/blood-2018-07-863829","journal-title":"Blood"},{"key":"4637_CR10","unstructured":"GSK GmbH DREAMM-3 Announcement GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation | GSK. In: GSK Belantamab Mafodotin Statment. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/. Accessed 31 Jan 2023"},{"key":"4637_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","volume":"122","author":"A Larocca","year":"2013","unstructured":"Larocca A, Montefusco V, Bringhen S et al (2013) Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study. Blood 122:2799\u20132806. https:\/\/doi.org\/10.1182\/blood-2013-03-488676","journal-title":"Blood"},{"key":"4637_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ et al (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:1551\u20131560. https:\/\/doi.org\/10.1016\/S0140-6736(15)01120-4","journal-title":"Lancet"},{"key":"4637_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","author":"S Lonial","year":"2019","unstructured":"Lonial S, Lee HC, Badros A et al (2019) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"4637_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Weisel K, De Stefano V et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36:1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"key":"4637_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet 394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","journal-title":"The Lancet"},{"key":"4637_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"4637_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"4637_CR18","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/cncr.32178","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Joseph NS, Kaufman JL et al (2019) Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer 125:2991\u20133000. https:\/\/doi.org\/10.1002\/cncr.32178","journal-title":"Cancer"},{"key":"4637_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754\u2013766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"key":"4637_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20:781\u2013794. https:\/\/doi.org\/10.1016\/S1470-2045(19)30152-4","journal-title":"Lancet Oncol"},{"key":"4637_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P et al (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055\u20131066. https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"key":"4637_CR22","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","volume":"61","author":"O Van Oekelen","year":"2020","unstructured":"Van Oekelen O, Parekh S, Cho HJ et al (2020) A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma. Leuk Lymphoma 61:2208\u20132215. https:\/\/doi.org\/10.1080\/10428194.2020.1805111","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04637-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04637-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:23:56Z","timestamp":1689769436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04637-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4637"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04637-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB has participated in advisory boards from BMS\/Celgene, Janssen, GSK, Takeda, and Sanofi and received honoraria and travel support from BMS\/Celgene, Janssen, GSK, Sanofi, AMGEN, Gilead, and Takeda; KM has received honoraria from BMS\/Celgene, Janssen, Amgen, Takeda, Pfizer, GSK, and Sanofi; MB has received honoraria from BMS\/Celgene; FHH has received research funding from BMS\/Celgene and served as an advisor for BMS\/Celgene and Janssen; TS has participated in advisory boards from Novartis, has received honoraria from Novartis, Amgen, Alexion, Janssen, AOP, BMS, Grifols and has received research support from Novartis, Amgen, Sobi, Argenx, and Grifols; EZ has received honoraria and is an advisory board member for BMS\/Celgene, Janssen, Amgen, Sanofi, GSK; AH received research support by Novartis, BMS\/Celgene, Pfizer, and Incyte; MvLT has received honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merk, CDDF, AbbVie, AstraZeneca, Pfizer, Thermofisher, GSK, and Shionogi and research funding from BMBF, Deutsch Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung, IZKF Jena, DFG, Novartis, Gilead, Deutsche Krebshilfe, BMS\/Celgene, Oncopeptides. All the other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}